Track topics on Twitter Track topics that are important to you
Boehringer Ingelheim has exercised its option to buy ViraTherapeutics for €210 million ($245 million), the buyer and the acquired company’s co-lead investor EMBL Ventures said today, in a deal that gives Boehringer full control over a preclinical viral-based cancer immunotherapy the companies have been co-developing for two years. EMBL Ventures is an early-stage European life science venture capital firm that first invested in the Company in 2015 as part of its €3.6 million ($4.2 million) Series A financing round. A year later, EMBL partnered with the German pharma’s Boehringer Ingelheim Venture Fund—whose areas of investment focus include immuno-oncology—to serve as co-lead investors in ViraTherapeutics. The investments occurred when Boehringer Ingelheim agreed to co-develop ViraTherapeutics’ oncolytic virus therapy platform and lead candidate , the solid tumor treatment vesicular stomatitis virus with modified glycoprotein (VSV-GP), alone and in combination therapies, through a collaboration that gave Boehringer Ingelheim rights to ...NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...